According to a recent study and meta-analysis, trough levels of ＞10 mg/mL teicoplanin (TEIC) may be acceptable for the treatment of uncomplicated infection, but no method of TEIC personalized medicine has been established. Vancomycin (VCM) and TEIC are glycopeptide antibiotic agents eŠective against methicillin-resistance Staphyloccocus aureus. This study aimed to establish TEIC personalized medicine at a steady state calculated by VCM pharmacokinetic parameters. Bayesian forecasting and population mean methods were employed to estimate individual total VCM clearance (CL) using existing population pharmacokinetics (PPK) parameter, and the diŠerences between the CL calculated by these two methods were deˆned as DCL. Serum drug concentration data for patients treated with TEIC were collected at a steady state concentration (＞96 h post infusion). There was a signiˆcant relationship between the prediction error of TEIC trough level and DCL. The relation between DCL and TEIC trough concentration at steady state was used to develop the following equation to determine the maintenance dose: TEIC (mg/mL)＝1.1119X-6.124DCL＋3.9164 (X is deˆned as TEIC trough concentration calculated from the PPK parameter). The results of this study indicated that it is possible to improve the prediction error of TEIC trough concentration at a steady state for patients who have received VCM therapy.